PrognomiQ announced the initial launch of its ProVue blood test while Mercy presented new data detailing the performance of its Halo lung cancer test.

The test is intended for patients with moderate to severe depression and differentiates between unipolar and bipolar depression.

Exact Sciences shareholders will receive $105 per common share as part of the deal, which is expected to close in the second quarter of 2026.

With the transaction, which Bloomberg News said could be announced within the next several days, Abbott would acquire tests including Exact's Cologuard, among other tests.